Loading organizations...
§ Private Profile · 201 Brookline Ave Suite 1002 (10th floor) Boston, MA 02215
Biotechnology company developing antibody-based medicines for serious diseases.
Mediar Therapeutics develops first-in-class therapies engineered to halt and potentially reverse fibrotic activity in various organ systems. The company's innovative approach targets the myofibroblast, a key pathogenic cell responsible for driving scarring and disease progression, aiming to deactivate it rather than merely addressing symptoms. This novel strategy focuses on unexplored biological pathways to disrupt the underlying mechanisms of fibrosis.
The company began its operations in 2019, with Rahul Ballal, PhD, as CEO and Paul Yaworsky, PhD, as CSO, both instrumental in advancing its scientific direction. The foundational insight stemmed from a deep understanding of fibrosis progression and the critical role myofibroblasts play in this process. Dr. Yaworsky's extensive background in drug discovery and development underpinned the scientific rigor applied from inception.
Mediar Therapeutics’ products are designed for patients suffering from devastating fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis (SSc), currently undergoing clinical trials. The company's long-term vision is to provide meaningful impact and hope to these patients by fearlessly pioneering novel therapeutic options where current treatments fall short.
Mediar Therapeutics has raised $161.0M across 2 funding rounds.
Mediar Therapeutics has raised $161.0M in total across 2 funding rounds.
Mediar Therapeutics has raised $161.0M across 2 funding rounds. Most recently, it raised $76.0M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 7, 2026 | $76M Series B | Allan Marchington, Bharat Srinivasa | Alexandria Venture Investments, Asahi Kasei Pharma, Longwood Fund | Announced |
| Mar 1, 2023 | $85M Series A | — | Soffinova Partners, SV Health Investors | Announced |
Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies to halt and reverse fibrosis by targeting the myofibroblast, the key cell driving scarring and organ failure in fibrotic diseases.[1][2][3][5][6] It serves patients with conditions like idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis, addressing the unmet need for therapies that interrupt disease progression beyond symptom management, using novel targets detectable via blood biomarkers for precision medicine.[3][5][6] The company has shown strong growth momentum, raising $105 million in Series A financing in 2023, advancing multiple programs into clinical trials—including Phase 2 dosing for lead candidate MTX-463 in IPF—and securing a global licensing deal with Eli Lilly in 2025.[3][4][5]
Mediar Therapeutics was founded in 2018 (with some sources noting 2019) based on pioneering fibrosis research from Mass General and Brigham & Women’s Hospitals, in partnership with Mass General Brigham Ventures, targeting the myofibroblast as a key driver of fibrotic disease progression.[1][2][3][4] Key founders include Chief Scientific Officer Paul Yaworsky, drawing from deep scientific expertise in fibrosis biology, while industry veteran Rahul Ballal, Ph.D., serves as CEO to lead clinical advancement.[3][4] Early traction came from nominating clinical candidates and raising $105 million in 2023 Series A funding co-led by Novartis Venture Fund and Sofinnova Partners, with participation from Pfizer Ventures, Gimv, Eli Lilly, and others, enabling rapid progression to human trials.[1][2][3]
Mediar rides the wave of precision biologics in fibrosis, a market long underserved with few approved therapies, amid rising demand driven by aging populations and chronic diseases like IPF and SSc.[1][5][6] Timing aligns with advances in myofibroblast biology and biomarker tech, enabling targeted interventions over broad immunosuppressants, fueled by investor interest in de-risked biopharma (e.g., $105M raise).[3] It influences the ecosystem by pioneering myofibroblast-focused platforms, partnering with pharma giants like Lilly, and advancing multiple modalities, potentially reshaping fibrosis treatment standards and attracting follow-on innovation in organ-specific therapies.[2][5]
Mediar is poised for milestone-rich 2025-2026, with MTX-474 Phase 2 initiation in SSc, SMOC2 candidate advancement for kidney fibrosis, and Lilly-driven Phase 2 data from MTX-463 in IPF, building on first-patient dosing in mid-2025.[4][5][6] Trends like AI-enabled biomarker discovery and combo therapies will shape its path, amplifying precision fibrosis efforts amid regulatory tailwinds for rare diseases. Its influence could expand via further partnerships or approvals, transforming it from pioneer to fibrosis leader—echoing its founding mission to halt disease at the myofibroblast source.[1][3][5]
Mediar Therapeutics has raised $161.0M in total across 2 funding rounds.
Mediar Therapeutics's investors include Allan Marchington, Bharat Srinivasa, Alexandria Venture Investments, Asahi Kasei Pharma, Longwood Fund, Soffinova Partners, SV Health Investors.